Sarepta Therapeutics | SRPT - Gross Profit On Sales


Sarepta Therapeutics reported $621.34M in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 243.27M 14.49M Mar/2026
Agios Pharmaceuticals USD 19.43M 1.34M Mar/2026
Alnylam Pharmaceuticals USD 825M 4.3M Mar/2026
Amgen USD 6.89B 415M Dec/2025
BioCryst Pharmaceuticals USD 153.05M 4.16M Dec/2025
Biogen USD 1.82B 169.5M Mar/2026
BioMarin Pharmaceutical USD 571.21M 141.8M Mar/2026
Capricor Therapeutics 11.13M 8.87M Dec/2024
Daiichi Sankyo JPY 439.83B 95.05B Dec/2025
Eli Lilly USD 15.92B 1.33B Dec/2025
Esperion Therapeutics USD 140.59M 94.57M Dec/2025
Gilead Sciences USD 5.52B 791M Mar/2026
Incyte USD 1.17B 217.51M Mar/2026
Insmed USD 256.46M 38.78M Mar/2026
Ionis Pharmaceuticals USD 243M 48M Mar/2026
Moderna USD -566M 792M Mar/2026
Nektar Therapeutics USD 21.81M 8.06M Dec/2025
Neurocrine Biosciences USD 800.7M 12.8M Mar/2026
Novavax USD 125.04M 76.09M Dec/2025
Pfizer USD 11.04B 1.24B Mar/2026
PTC Therapeutics USD 232.94M 84.56M Mar/2026
Regeneron Pharmaceuticals USD 2.94B 363.7M Mar/2026
Roche Holding CHF 22.09B 10.04B Dec/2025
Sangamo BioSciences -2.39M 1.09M Jun/2024
Sanofi EUR 8.45B 1.31B Dec/2025
Sarepta Therapeutics USD 621.34M 577.79M Mar/2026
Tectonic Therapeutic USD 0 0 Mar/2025
Ultragenyx Pharmaceutical USD 106M 72M Mar/2026
Vertex Pharmaceuticals USD 2.6B 121.7M Mar/2026